ESR1 and breast carcinoma: Exogenous expression of ∆DCCDC170 in ER+ breast cancer cells led to enhanced growth and reduced sensitivity to tamoxifen[73] suggesting a role for ESR1-e2>CCDC170 in endocrine therapy resistance.